Cargando…

Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials

OBJECTIVES: To assess the efficacy and safety profile of add‐on cannabidiol (CBD) in patients with Lennox–Gastaut syndrome (LGS) and Dravet syndrome (DS) on clobazam and in the overall population of four randomized, controlled phase 3 trials. METHODS: Patients received plant‐derived, highly purified...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gunning, Boudewijn, Mazurkiewicz‐Bełdzińska, Maria, Chin, Richard F. M., Bhathal, Hari, Nortvedt, Charlotte, Dunayevich, Eduardo, Checketts, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7821324/ https://www.ncbi.nlm.nih.gov/pubmed/32969022 http://dx.doi.org/10.1111/ane.13351

Ejemplares similares

Cannabidiol efficacy independent of clobazam: Meta‐analysis of four randomized controlled trials
por: Devinsky, Orrin, et al.
Publicado: (2020)

Cannabidiol in patients with Lennox‐Gastaut syndrome: Interim analysis of an open‐label extension study
por: Thiele, Elizabeth, et al.
Publicado: (2019)

Time to onset of cannabidiol (CBD) treatment effect in Lennox–Gastaut syndrome: Analysis from two randomized controlled trials
por: Privitera, Michael, et al.
Publicado: (2021)

Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials
por: Madan Cohen, Jennifer, et al.
Publicado: (2021)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
por: Anderson, Lyndsey L., et al.
Publicado: (2019)

Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial
por: Thiele, Elizabeth A., et al.
Publicado: (2020)

A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020)

Clobazam and Its Use in Epilepsy
por: Pernea, Marius, et al.
Publicado: (2016)

The clobazam metabolite N-desmethyl clobazam is an α2 preferring benzodiazepine with an improved therapeutic window for antihyperalgesia
por: Ralvenius, William T., et al.
Publicado: (2016)

A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019)

Hypothermia associated with clobazam use in adult epilepsy
por: Gauthier, Angela C., et al.
Publicado: (2016)

A CONTROL CLINICIAL TRIAL OF A NEW ANXIOLYTIC ‘CLOBAZAM’
por: Singh, Gurmeet, et al.
Publicado: (1984)

Effect of plasmapheresis on serum levels of clobazam, levetiracetam and topiramate
por: Hau Man, To Harmony, et al.
Publicado: (2017)

Effects of clobazam for treatment of refractory status epilepticus
por: Madžar, Dominik, et al.
Publicado: (2016)

A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam
por: Tolbert, Dwain, et al.
Publicado: (2018)

Effect of clobazam as add-on antiepileptic drug in patients with epilepsy
por: Joshi, Rupa, et al.
Publicado: (2014)

Systematic review of clobazam use in patients with status epilepticus
por: Mahmoud, Sherif Hanafy, et al.
Publicado: (2018)

A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
por: Ben-Menachem, Elinor, et al.
Publicado: (2020)

Milestones in genetics of cerebellar ataxias
por: Krygier, Magdalena, et al.
Publicado: (2021)

CLOBAZAM SINGLE OR DIVIDED DOSE AGAINST DIAZEPAM IN ANXIETY NEUROSIS
por: Channabasavanna, S.M., et al.
Publicado: (1986)

Clobazam: The phoenix drug (from the very old to the brand new)
por: Guerreiro, Carlos A. M.
Publicado: (2014)

Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
por: Leahy, Jennifer T, et al.
Publicado: (2011)

Design Optimization and In Vitro-In Vivo Evaluation of Orally Dissolving Strips of Clobazam
por: Bala, Rajni, et al.
Publicado: (2014)

Rare but life-threatening aspiration pneumonia related to initiation of clobazam therapy
por: Aung, Thandar, et al.
Publicado: (2020)

Macroglossia Associated With Clobazam Administration: A Case Report and Literature Review
por: Zhang, Jeff F., et al.
Publicado: (2022)

Development of the Method for Nusinersen and Its Metabolites Identification in the Serum Samples of Children Treated with Spinraza for Spinal Muscular Atrophy
por: Studzińska, Sylwia, et al.
Publicado: (2022)

Comprehensive overview: efficacy, tolerability, and cost-effectiveness of clobazam in Lennox–Gastaut syndrome
por: Faulkner, Michele A
Publicado: (2015)

Impairment of cognitive functions in children and adolescents with focal epilepsy
por: Domańska, Martyna, et al.
Publicado: (2023)

Phenytoin induced chorea in a pediatric patient: An interaction between phenytoin, phenobarbital and clobazam
por: Barvaliya, Manish, et al.
Publicado: (2011)

Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series
por: Sankar, Raman, et al.
Publicado: (2014)

Does orally dissolving formulation of clobazam provide clinical advantage over it's standard formulation
por: Patil, Anant Dhondopant
Publicado: (2016)

Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study
por: Gidal, Barry E., et al.
Publicado: (2016)

Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome
por: François, Clément, et al.
Publicado: (2017)

Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
por: Wu, Joyce Y., et al.
Publicado: (2022)

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
por: Devinsky, Orrin, et al.
Publicado: (2018)

Corticosteroids versus clobazam in epileptic encephalopathy with ESES: a European multicentre randomised controlled clinical trial (RESCUE ESES*)
por: van den Munckhof, Bart, et al.
Publicado: (2020)

A stability indicating HPLC method for the determination of clobazam and its basic degradation product characterization
por: Souri, Effat, et al.
Publicado: (2014)

Retrospective analysis of metabolite patterns of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS
por: Bajaj, Amol O., et al.
Publicado: (2022)

Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
por: Serrano-Castro, Pedro J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oa8dllgqck5djvnde3m8pko09p